drugset / Trial / NCT01001767
Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease
Phase 2
Completed
35 enrolled
University Hospitals Cleveland Medical Center
Case Western Reserve University · collabGlaxoSmithKline · collabThe Campbell Foundation · collab
RandomizedParallel-groupTriple-blind
Summary
Several studies have shown that there is an increased risk of heart disease in people with HIV. In this study the investigators are looking at the effect of Lovaza (Omega-3 fatty acid) on improving endothelial function and decreasing inflammation which may contribute to this increased risk. The investigators will also be doing studies to analyze coagulation and inflammation markers.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-03
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lovaza | Other / unclassified | 1 g | Oral |